Bharat Biotech’s Covid-19 Vaccine ‘Covaxin’ Goes Into Phase-3 Trials
BharatBiotech in September stated it participated in a licensing contract with Washington University School of Medication in St. Louis for a novel “chimp-adenovirus” (Chimpanzee adenovirus), single dosage intranasal vaccine for COVID-19
- PTI Hyderabad
- Last Upgraded: November 16, 2020, 16: 41 IST
- FOLLOW US ON:
Covid-19 vaccine, Covaxin, being developed by Bharat Biotech is now going through phase-3 trials, Krishna Ella, Chairman and Handling Director, Bharat Biotech said on Monday. Speaking practically at a program organised by the Indian School of Service, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be all set by next year.
” We partnered with ICMR for COVID-19 vaccine as we speak it entered the stage 3 trials,” he said. Bharat Biotech is the only vaccine business in the world which has BSL3 production center (Biosafety level 3), he said.
Last month the vaccine maker stated it had effectively finished interim analysis of Phase I and II trials of the vaccine and is starting Phase-III trials in 26,000 participants. Covaxinis being established byBharatBiotech, in collaboration with the Indian Council of Medical Research (ICMR)– National Institute of Virology (NIV).
The city-based vaccine maker had on October 2 sought the Drug Controller General of India’s (DCGI) authorization to conduct stage 3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine, sources said. “We are dealing with another vaccine through nasal drops my feeling is by next year it will reach the population,” Ella said.
BharatBiotech in September said it participated in a licensing contract with Washington University School of Medicine in St. Louis for a novel “chimp-adenovirus” (Chimpanzee adenovirus), single dose intranasal vaccine for COVID-19
( the heading, this story has not been released by Important India News personnel and is published from a syndicated feed.).